OraSure can't dump Abbott but it can have extra partners
This article was originally published in Clinica
OraSure Technologies is not permitted to cancel its arrangement with Abbott Laboratories for the sale of its OraQuick rapid HIV-1 antibody tests, but it will in future be allowed to sign additional distribution partners. So said a US arbitrator, whose decision is final and may not be appealed by either of the former disputants.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.